AKTS (Aktis Oncology) Earnings Power Value (EPV): $10.84 (As of Mar26)


AKTS Aktis Oncology Inc AKTS
9 GF Score
Price $29.37
! 3 Warning Signs
View Full Analysis

What is Aktis Oncology Earnings Power Value (EPV)?

Aktis Oncology AKTS -5.49% 9 Earnings Power Value (EPV) is $10.84 as of Mar26. GuruFocus rates AKTS with a GF Score™ of 9/100. The stock has 3 warning signs investors should review.

As of Mar26, Aktis Oncology's earnings power value is $10.84. *

* GuruFocus does not store EPV value into our database if Average Maintenance CAPEX is 0.

Margin of Safety is N/A.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future. Assumption: Current profitability is sustainable.

Aktis Oncology  (NAS:AKTS) Earnings Power Value (EPV) Explanation

Assumption: Current profitability is sustainable.

Earnings power value (EPV) uses a very basic equation which assumes no growth, although it does rely on an assumption about the cost of capital as well as the fact that current earnings are sustainable. It also involves several adjustments to clean up the underlying Earnings figures.

Be Aware

Though using today's earnings in calculating Earnings Power Value, GuruFocus is normalizing these earnings to the business cycle. This eliminates the effects on profitability of valuing the firm at different points in the business cycle. This means that we are considering the average earnings over 5 years.

Aktis Oncology Earnings Power Value (EPV) Related Terms

Aktis Oncology Earnings Power Value (EPV) Historical Data

* Premium members only.

The historical data trend for Aktis Oncology's Earnings Power Value (EPV) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aktis Oncology Earnings Power Value (EPV) Chart

Aktis Oncology Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Earnings Power Value (EPV)
0.00 0.00 0.00 0.00

Aktis Oncology Quarterly Data
Dec22 Dec23 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
Earnings Power Value (EPV) Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

AKTS vs OLMA, EYPT, ZBIO: Earnings Power Value (EPV) Comparison

For the Biotechnology subindustry, Aktis Oncology's Earnings Power Value (EPV), along with its competitors' market caps and Earnings Power Value (EPV) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Aktis Oncology Earnings Power Value (EPV) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aktis Oncology's Earnings Power Value (EPV) distribution charts can be found below:

* The bar in red indicates where Aktis Oncology's Earnings Power Value (EPV) falls into.


AKTS
9GF Score
Aktis Oncology Inc AKTS
Earnings Power Value (EPV) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aktis Oncology Earnings Power Value (EPV) Calculation

Earnings Power Value also known as just Earnings Power is a valuation technique popularised by Bruce Greenwald, an authority on value investing at Columbia University. It is arguably a better way to analyze stocks than Discounted Cash Flow analysis that relies on highly speculative growth assumptions many years into the future.

The basic concept of EPV is that one should value a stock based on the current free cash flow of a company and not on future projections which may, or may not, come true. This valuation tool excludes the potential growth that a company may have so that needs to be looked at separately. Since future growth is excluded from the analysis, only the maintenance capital expenditures are subtracted from after-tax EBIT (earnings before interest and taxes) and growth capex is ignored.

What does a Earnings Power Value (EPV) of $10.84 mean?
Aktis Oncology (AKTS) has a Earnings Power Value (EPV) of $10.84 as of Mar26. Bruce Greenwald's earnings power value focuses on current earnings without factoring in future growth. View historical data on Aktis Oncology and its competitors.
Is Aktis Oncology's Earnings Power Value (EPV) too high?
Aktis Oncology's current Earnings Power Value (EPV) is $10.84. Overall, Aktis Oncology has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Aktis Oncology's Earnings Power Value (EPV) compare to OLMA and EYPT?
Aktis Oncology's Earnings Power Value (EPV) of $10.84 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings Power Value (EPV) for a Biotechnology company?
A good Earnings Power Value (EPV) depends on the Biotechnology industry context. However, Earnings Power Value (EPV) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings Power Value (EPV) mean?
A high Earnings Power Value (EPV) can signal that a stock is expensive relative to its fundamentals. Bruce Greenwald's earnings power value focuses on current earnings without factoring in future growth. View historical data on Aktis Oncology and its competitors. Aktis Oncology's current Earnings Power Value (EPV) is $10.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aktis Oncology stock overvalued right now?
Aktis Oncology (AKTS) has a current Earnings Power Value (EPV) of $10.84. The current Earnings Power Value (EPV) is $10.84. Aktis Oncology's overall GF Score™ is 9/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings Power Value (EPV) calculated?
Earnings Power Value (EPV) is calculated from a company's financial statements. For Aktis Oncology (AKTS), the current Earnings Power Value (EPV) is $10.84 as of Mar26. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aktis Oncology Business Description

Address 17 Drydock Avenue, Suite 17-401, Boston, MA, USA, 02210
Aktis Oncology Inc is a clinical-stage oncology company focused on expanding the breakthrough potential of targeted radiopharmaceuticals to large patient populations, including those not addressed by existing platform technologies. The company specializes in developing targeted alpha radiopharmaceuticals for solid tumors such as breast, lung, colorectal, bladder, and liver cancers. Its pipeline products include AKY-1189 and AKY-2519, focusing on solid tumors. The company has one operating and reportable segment focused on the research and development of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. The company generates revenue from Collaboration agreement.
9GF Score

Get the complete analysis for AKTS

Earnings Power Value (EPV) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$29.37
Price